Joshua Ruch Sells 38,000 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Joshua Ruch sold 38,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $160.37, for a total value of $6,094,060.00. Following the completion of the sale, the director directly owned 11,941 shares of the company’s stock, valued at $1,914,978.17. The trade was a 76.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

GeneDx Stock Performance

NASDAQ:WGS opened at $165.61 on Friday. The firm has a market capitalization of $4.79 billion, a PE ratio of 1,840.11 and a beta of 2.01. The stock’s fifty day moving average is $130.01 and its 200 day moving average is $106.42. GeneDx Holdings Corp. has a fifty-two week low of $55.17 and a fifty-two week high of $170.75. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. The business had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. GeneDx has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Canaccord Genuity Group set a $160.00 price objective on shares of GeneDx and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Piper Sandler raised their price target on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, September 11th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. BTIG Research increased their target price on GeneDx from $140.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and a consensus price target of $129.22.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Quarry LP raised its holdings in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares in the last quarter. US Bancorp DE lifted its stake in GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares during the period. Gordian Capital Singapore Pte Ltd bought a new position in GeneDx during the 3rd quarter worth about $65,000. Finally, AlphaQuest LLC grew its holdings in GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after acquiring an additional 594 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.